# Camizestrant

**Cat. No.:** HY-136255

**CAS No.:** 2222844-89-3

**Molecular Formula:** $C_{24}H_{28}F_4N_6$

**Molecular Weight:** 477

**Target:** Estrogen Receptor/ERR

**Pathway:** Vitamin D Related/Nuclear Receptor

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 2 years |
| | -20°C | 1 year |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (209.64 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.0964 mL | 10.4822 mL | 20.9644 mL |
| | 5 mM | 0.4193 mL | 2.0964 mL | 4.1929 mL |
| | 10 mM | 0.2096 mL | 1.0482 mL | 2.0964 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 7.5 mg/mL (15.72 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 7.5 mg/mL (15.72 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 7.5 mg/mL (15.72 mM); Clear solution
4. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
   Solubility: 2.5 mg/mL (5.24 mM); Suspended solution; Need ultrasonic
5. Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (5.24 mM); Suspended solution; Need ultrasonic

## BIOLOGICAL ACTIVITY

**Description**

Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of $ER^+$ HER2-advanced breast cancer[1].

| | |
|---|---|
| **$IC_{50}$ & Target** | IC50: estrogen receptor (ER)[1] |
| **In Vitro** | Camizestrant is extracted from patent US20180111931A1, example 17[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| **In Vivo** | Camizestrant (oral administration; 0.2-50 mg/kg; 20 days) exhibits anti-tumour efficacy as a dose-dependent manner in human parental MCF7 mice xenograft[1].<br>Camizestrant (oral administration; 0.8-40 mg/kg; 30 days) decreases tumor growth as a dose-dependent manner. It gives almost complete tumour growth inhibition at the doses >10 mg/kg in mice[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| | |
|---|---|
| Animal Model: | Human ESR1 mutant breast cancer patient derived xenograft with CTC174 cells in female NSG mice[1] |
| Dosage: | 0.8 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg |
| Administration: | Oral administration; 30 days; once daily |
| Result: | Inhibited tumor growth in a dose-dependent manner. |

## CUSTOMER VALIDATION

- bioRxiv. 2023 Nov 2.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Bernard Christophe Barlaam, etal. Chemical compounds. Patent US20180111931.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA